Inhibition of histone deacetylase for the treatment of biliary tract cancer: A new effective pharmacological approach

Figure 3 In vivo treatment with NVP-LBH589 ± gemcitabine in chimeric mice. A: Effect on tumor volume of EGI-1 cells (^aP < 0.05, NVP-LBH589 vs control; ^cP < 0.05, COMBO vs control); B: Effect on tumor volume of Mz-ChA-2 cells (^aP < 0.05, ^bP < 0.01, NVP-LBH589 vs control; ^cP < 0.05, ^dP < 0.01, COMBO vs control; ^fP < 0.01, gemcitabine vs control); C: Effect on tumor mass (^aP < 0.05, NVP-LBH589 or COMBO vs control; ^bP < 0.01, NVP-LBH589 or COMBO or gemcitabine vs control).